Compare YHC & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | AIDX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Precision Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.5M |
| IPO Year | N/A | N/A |
| Metric | YHC | AIDX |
|---|---|---|
| Price | $0.80 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.7K | ★ 56.6K |
| Earning Date | 04-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,267.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.45 |
| 52 Week High | $11.14 | $14.09 |
| Indicator | YHC | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 23.81 |
| Support Level | $0.79 | $1.51 |
| Resistance Level | $0.94 | $2.08 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 33.61 | 37.50 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.